RashTREATSNCT07476807
Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study
A study testing telem healthassessment in people with Rash and Systemic Treatments, run by Sligo General Hospital at 1 site in Ireland.
Trial summary
This study is being done to find out if video consultations (telemedicine) can be used to safely and effectively assess and manage skin problems caused by cancer treatments. Instead of always coming to the hospital for a face-to-face appointment, the patient may be able to use thier smartphone or computer to show your… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Rash, Systemic Treatments, Tele-assessment
- What is being tested?
- telem healthassessment
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- 1 siteIreland
- Study dates
- 1 Apr 2026to 12 Sep 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Inclusion Criteria:Participants must meet all of the following criteria:
- Adult oncology or haematology patients currently receiving systemic anti-cancer therapy (SACT).
- New-onset dermatologic toxicity consistent with a recognised adverse effect of the administered SACT.
- Skin toxicity severity graded ≤ Grade 2 in accordance with UKONS assessment criteria.
- Clinically stable condition not requiring urgent in-person evaluation.
- Access to, and ability to use, a smartphone or computer with adequate internet connectivity to participate in telemedicine consultations.
Exclusion Criteria: Participants will be excluded if any of the following criteria apply:
- Skin toxicity graded ≥ Grade 3 according to UKONS assessment criteria.
- Clinical status requiring urgent or immediate face-to-face medical assessment.
- Dermatologic toxicity that is atypical, unexpected, or not consistent with known SACT-related adverse effects.
- Inability to access or effectively use the required telemedicine technology.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: TREATS: Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study
This study is being done to find out if video consultations (telemedicine) can be used to safely and effectively assess and manage skin problems caused by cancer treatments. Instead of always coming to the hospital for a face-to-face appointment, the patient may be able to use thier smartphone or computer to show your skin to a nurse or doctor over a secure video call. the researchers want to see if this is as good as a regular clinic visit, and whether patients and staff are happy with this new way of working.
- Conditions
- Rash, Systemic Treatments, Tele-assessment
- Being tested
- telem healthassessment
- Medical subject headings
- Exanthema
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
telem healthassessmentOther
SOC is face to face assessment-this study aims to use telemedecine toassess Treatment related skin disorders
| Study group | Role | What they receive |
|---|---|---|
| Remote tele medicine assessment | Other | use of telemedicine Receives: Other: telem healthassessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
time to clinical resolution
Number of days from first AHOS contact to documented resolution (Grade 0-1).
Measured: 6 weeks
Secondary outcomes (4)
Escalation in person review
Proportion of telemedicine patients requiring:
- Conversion to face-to-face review
- Emergency department attendance
- Hospital admission
Measured: 6 weeks
treatment modification reat
Proportion of telemedicine patients requiring:
- Conversion to face-to-face review
- Emergency department attendance
- Hospital admission
Measured: 6 weeks
unscheduled acute contact
Number of unplanned re-contacts with AHOS
Measured: 6 weeks
Patient-Reported Endpoints -Quality of Life (QoL) and patient satisfaction
Instrument:
QLQ administered:
- Post initial assessment
- At resolution or week 6
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2026
- Study start1 Apr 2026
- Primary completion1 Apr 2026
- Study completion12 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for RashStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sligo General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Margaret Burke, Sligo General Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07476807
- Sponsor's protocol ID
- 1067SUHREC
- Acronym
- TREATS
- Status last verified
- Apr 2026
- First submitted
- 27 Feb 2026
- Last updated
- 28 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- TREATS: Telemedicine Rash Evaluation and Assessment of Toxicity in Skin in Acute Oncology and Haematology Care: A Pilot Study
- ClinicalTrials.gov ID
- NCT07476807
- Acronym / sponsor ID
- TREATS / 1067SUHREC
- Conditions
- Rash, Systemic Treatments, Tele-assessment
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- Sligo General HospitalUniversity, hospital or other
- Study start
- 1 Apr 2026 (actual)
- Primary completion
- 1 Apr 2026 (actual)
- Study completion
- 12 Sep 2026 (estimated)
- First posted
- 17 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is being done to find out if video consultations (telemedicine) can be used to safely and effectively assess and manage skin problems caused by cancer treatments. Instead of always coming to the hospital for a face-to-face appointment, the patient may be able to use thier smartphone or computer to show your skin to a nurse or doctor over a secure video call. the researchers want to see if this is as good as a regular clinic visit, and whether patients and staff are happy with this new way of working.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Remote tele medicine assessment | Other | Other: telem healthassessmentuse of telemedicine |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| telem healthassessmentSOC is face to face assessment-this study aims to use telemedecine toassess Treatment related skin disorders | Other | Remote tele medicine assessment |
Primary outcome
time to clinical resolution
Time frame: 6 weeks
Number of days from first AHOS contact to documented resolution (Grade 0-1).
4 secondary outcomes
Escalation in person review
Time frame: 6 weeks
treatment modification reat
Time frame: 6 weeks
unscheduled acute contact
Time frame: 6 weeks
Patient-Reported Endpoints -Quality of Life (QoL) and patient satisfaction
Time frame: 6 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Apr 2026.
Related trials for Rash
Not yet recruitingPhase 3
Evaluation of the Efficacy and Safety of Fractional CO₂ Laser With and Without Intradermal Botulinum Toxin A in the Treatment of Inflammatory Facial Acne Vulgaris.
Acne, Acne Papulopustulosa
RecruitingPhase 4
Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Gel (Klenzit®-C) in Vietnamese Patients With Mild to Moderate Acne Vulgaris
Acne
RecruitingPhase 3
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Acne Vulgaris
RecruitingPhase 4
Comparing Nadifloxacin Plus Tretinoin Versus Clindamycin Plus Tretinoin Creams for Mild-to-Moderate Acne
Acne Vulgaris
RecruitingObservational study
A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab
Recurrent Mycosis Fungoides, Recurrent Sezary Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing telem healthassessment in people with Rash and Systemic Treatments, run by Sligo General Hospital at 1 site in Ireland.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 28 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
time to clinical resolution (time frame: 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Apr 2026.